Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sulzer Cervical Fusion System Gains Panel Nod; Firm May Be First To Market

This article was originally published in The Gray Sheet

Executive Summary

Sulzer Spine-Tech should perform a sensitivity analysis on existing data to make a stronger case that patients who dropped out of the study's control group did not bias conclusions in favor of the firm's BAK/C cervical interbody fusion system, FDA's Orthopedic and Rehabilitation Devices panel recommended.

You may also be interested in...

Sulzer Medica's BAK/C

FDA "approvable" letter for the cervical interbody fusion system is received March 19. The agency's Orthopedic and Rehabilitation Devices Panel unanimously recommended approval of a premarket approval application for the device Jan. 19 (1"The Gray Sheet" Jan. 22, 2001, p. 13). Sulzer estimates the cervical fusion market at approximately $160 mil. this year and annual growth of 19%. Upon final approval by FDA, the BAK/C will be the first cervical interbody fusion device to reach the U.S. market

Finance Watch: Silverback, Kinnate, Sigilon Launch December’s First IPOs

Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts